U.S. Markets are not yet open, but IMGN is being traded in the pre-market session. Pre-Market quote »
|12.84|| 0.00 / 0.00%|
ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. It also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell. The company also uses antibody-drug conjugate targeted antibody payload technology together with strong antibody expertise to develop its own product candidates. ImmunoGen was founded in March 1981 and is headquartered in Waltham, MA.
|Daniel M. Junius||President, Chief Executive Officer & Director|
|David B. Johnston||Chief Financial Officer & Executive Vice President|
|Sandra E. Poole||Executive Vice President-Technical Operations|
|Richard J. Gregory||Chief Scientific Officer & Executive VP-Research|
|Anna Berkenblit||Chief Medical Officer & Vice President|